An Open-label Trial to Assess the Efficacy and Safety of Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression

Trial Profile

An Open-label Trial to Assess the Efficacy and Safety of Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Immune-mediated uveitis; Juvenile rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2016 Status changed from recruiting to discontinued due to insufficient enrolment as reported by ClinicalTrials.gov.
    • 21 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top